(HealthDay News) The Rhinix nasal filter seems to be beneficial for adults with allergic rhinitis, according to a letter to the editor published online March 3 in the Journal of Allergy and Clinical Immunology.
Peter Kenney, from Aarhus University in Denmark, and colleagues conducted a randomized controlled trial to examine the efficacy, safety, and usability of a new nasal filter, Rhinix. Twenty-four adults with a history of grass pollen-induced allergic rhinitis were randomized to Rhinix or placebo. Participants were exposed to grass pollen in an environmental exposure unit for 210 minutes and rated their nasal symptoms at baseline and through 390 minutes of follow-up.
Three subjects were excluded from the analyses. The researchers found that there was a 14% mean and 33% median reduction in the total nasal symptom score with Rhinix versus placebo. Significant reductions were also seen in maximum nasal itching (P=0.004) and maximum and daily sneezing with Rhinix versus placebo (P=0.006 and 0.011, respectively). Rhinix also correlated with a significant reduction in throat irritation at 220 minutes (P=0.037), with a mean reduction of 75%, compared to placebo. Three subjects (two Rhinix-treated; one placebo-treated) experienced mild treatment-related adverse events.
“Rhinix appears useful in the treatment of seasonal allergic rhinitis; in-season studies on efficacy and usability (particularly concerning convenience, comfort, and treatment costs) in larger populations are needed to verify this,” the authors write.
One author disclosed financial ties to Rhinix ApS, which funded the study.